{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T05:54:03Z","timestamp":1790315643024,"version":"4.1.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1124\/jpet.123.002070","type":"journal-article","created":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T19:00:23Z","timestamp":1714158023000},"page":"389-398","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Antinociceptive Effects of \u03b12\/\u03b13-Subtype-Selective GABAA Receptor Positive Allosteric Modulators KRM-II-81 and NS16085 in Male Rats: Behavioral Specificity"],"prefix":"10.1016","volume":"391","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6080-636X","authenticated-orcid":false,"given":"Lakeisha A.","family":"Lewter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Woodhouse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.V.N. Phani Babu","family":"Tiruveedhula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Xu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.123.002070_bib1","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.pbb.2012.01.024","article-title":"Effects of imidazoline I(2) receptor agonists and morphine on schedule-controlled responding in rats","volume":"101","author":"An","year":"2012","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1124\/jpet.123.002070_bib2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.pharmthera.2009.09.001","article-title":"Preclinical and clinical pharmacology of the GABAA receptor alpha5 subtype-selective inverse agonist alpha5IA","volume":"125","author":"Atack","year":"2010","journal-title":"Pharmacol Ther"},{"key":"10.1124\/jpet.123.002070_bib3","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1124\/jpet.105.089920","article-title":"TPA023 [7-(1,1-dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine], an agonist selective for alpha2- and alpha3-containing GABAA receptors, is a nonsedating anxiolytic in rodents and primates","volume":"316","author":"Atack","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.123.002070_bib4","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1001\/archinte.163.20.2433","article-title":"Depression and pain comorbidity: a literature review","volume":"163","author":"Bair","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.1124\/jpet.123.002070_bib5","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0304-3959(88)90209-6","article-title":"A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man","volume":"33","author":"Bennett","year":"1988","journal-title":"Pain"},{"key":"10.1124\/jpet.123.002070_bib6","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/BF00470579","article-title":"Benzodiazepine antagonist Ro 15-1788: neurological and behavioral effects","volume":"78","author":"Bonetti","year":"1982","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/jpet.123.002070_bib7","doi-asserted-by":"crossref","first-page":"202","DOI":"10.3758\/BF03331928","article-title":"Memory deficits following diazepam administration in mice: evidence for a time-dependent retrieval impairment","volume":"25","author":"Borde","year":"1997","journal-title":"Psychobiology (Austin Tex)"},{"key":"10.1124\/jpet.123.002070_bib8","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1177\/0269881111405366","article-title":"Specific targeting of the GABA-A receptor \u03b15 subtype by a selective inverse agonist restores cognitive deficits in Down syndrome mice","volume":"25","author":"Braudeau","year":"2011","journal-title":"J Psychopharmacol"},{"key":"10.1124\/jpet.123.002070_bib9","doi-asserted-by":"crossref","first-page":"5572","DOI":"10.1523\/JNEUROSCI.22-13-05572.2002","article-title":"Enhanced learning and memory and altered GABAergic synaptic transmission in mice lacking the alpha 5 subunit of the GABAA receptor","volume":"22","author":"Collinson","year":"2002","journal-title":"J Neurosci"},{"key":"10.1124\/jpet.123.002070_bib10","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1192\/bjp.133.3.239","article-title":"Molecular mechanisms mediating the action of diazepam on GABA receptors","volume":"133","author":"Costa","year":"1978","journal-title":"Br J Psychiatry"},{"key":"10.1124\/jpet.123.002070_bib11","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/S0026-895X(24)12233-X","article-title":"Molecular targets for the myorelaxant action of diazepam","volume":"59","author":"Crestani","year":"2001","journal-title":"Mol Pharmacol"},{"key":"10.1124\/jpet.123.002070_bib12","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/bph.14153","article-title":"Experimental design and analysis and their reporting II: updated and simplified guidance for authors and peer reviewers","volume":"175","author":"Curtis","year":"2018","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.123.002070_bib13","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.bcp.2014.12.010","article-title":"GABAA \u03b15 subunit-containing receptors do not contribute to reversal of inflammatory-induced spinal sensitization as indicated by the unique selectivity profile of the GABAA receptor allosteric modulator NS16085","volume":"93","author":"de Lucas","year":"2015","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/jpet.123.002070_bib14","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/nprot.2006.2","article-title":"T-maze alternation in the rodent","volume":"1","author":"Deacon","year":"2006","journal-title":"Nat Protoc"},{"key":"10.1124\/jpet.123.002070_bib15","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.neuropharm.2010.11.026","article-title":"HZ166, a novel GABAA receptor subtype-selective benzodiazepine site ligand, is antihyperalgesic in mouse models of inflammatory and neuropathic pain","volume":"60","author":"Di Lio","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.123.002070_bib16","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.pharmthera.2012.08.006","article-title":"\u03b12-containing GABAA receptors: a target for the development of novel treatment strategies for CNS disorders","volume":"136","author":"Engin","year":"2012","journal-title":"Pharmacol Ther"},{"key":"10.1124\/jpet.123.002070_bib17","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.brainresbull.2017.03.001","article-title":"Pharmacological and antihyperalgesic properties of the novel \u03b12\/3 preferring GABAA receptor ligand MP-III-024","volume":"131","author":"Fischer","year":"2017","journal-title":"Brain Res Bull"},{"key":"10.1124\/jpet.123.002070_bib18","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/0091-3057(95)00063-3","article-title":"The benzodiazepine receptor inverse agonist RO 15-3505 reverses recent memory deficits in aged mice","volume":"51","author":"Forster","year":"1995","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1124\/jpet.123.002070_bib19","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1142\/S0219635212500045","article-title":"The place escape\/avoidance paradigm: a novel method to assess nociceptive processing","volume":"11","author":"Fuchs","year":"2012","journal-title":"J Integr Neurosci"},{"key":"10.1124\/jpet.123.002070_bib20","doi-asserted-by":"crossref","first-page":"5069","DOI":"10.2174\/1381612819666131216114612","article-title":"The role of \u03b15 GABAA receptor agonists in the treatment of cognitive deficits in schizophrenia","volume":"20","author":"Gill","year":"2014","journal-title":"Curr Pharm Des"},{"key":"10.1124\/jpet.123.002070_bib21","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1097\/j.pain.0000000000001267","article-title":"A randomised, placebo-controlled clinical trial with the \u03b12\/3\/5 subunit selective GABAA positive allosteric modulator PF-06372865 in patients with chronic low back pain","volume":"159","author":"Gurrell","year":"2018","journal-title":"Pain"},{"key":"10.1124\/jpet.123.002070_bib22","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/0304-3959(88)90026-7","article-title":"A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia","volume":"32","author":"Hargreaves","year":"1988","journal-title":"Pain"},{"key":"10.1124\/jpet.123.002070_bib23","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nature06493","article-title":"Reversal of pathological pain through specific spinal GABAA receptor subtypes","volume":"451","author":"Knabl","year":"2008","journal-title":"Nature"},{"key":"10.1124\/jpet.123.002070_bib24","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1006\/exnr.2000.7395","article-title":"A behavioral test paradigm to measure the aversive quality of inflammatory and neuropathic pain in rats","volume":"163","author":"LaBuda","year":"2000","journal-title":"Exp Neurol"},{"key":"10.1124\/jpet.123.002070_bib25","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1021\/acschemneuro.6b00447","article-title":"Antinociceptive effects of a novel alpha2\/alpha3-subtype selective GABAA receptor positive allosteric modulator","volume":"8","author":"Lewter","year":"2017","journal-title":"ACS Chem Neurosci"},{"key":"10.1124\/jpet.123.002070_bib26","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.bbr.2014.04.042","article-title":"Pain and depression comorbidity: a preclinical perspective","volume":"276","author":"Li","year":"2015","journal-title":"Behav Brain Res"},{"key":"10.1124\/jpet.123.002070_bib27","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1111\/bph.12555","article-title":"Antihyperalgesic effects of imidazoline I(2) receptor ligands in rat models of inflammatory and neuropathic pain","volume":"171","author":"Li","year":"2014","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.123.002070_bib28","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1126\/science.290.5489.131","article-title":"Molecular and neuronal substrate for the selective attenuation of anxiety","volume":"290","author":"L\u00f6w","year":"2000","journal-title":"Science"},{"key":"10.1124\/jpet.123.002070_bib29","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/75761","article-title":"Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABA(A) receptor alpha1 subtype","volume":"3","author":"McKernan","year":"2000","journal-title":"Nat Neurosci"},{"key":"10.1124\/jpet.123.002070_bib30","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1124\/jpet.108.138859","article-title":"NS11394 [3\u2032-[5-(1-hydroxy-1-methyl-ethyl)-benzoimidazol-1-yl]-biphenyl-2-carbonitrile], a unique subtype-selective GABAA receptor positive allosteric modulator: in vitro actions, pharmacokinetic properties and in vivo anxiolytic efficacy","volume":"327","author":"Mirza","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.123.002070_bib31","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1097\/FBP.0000000000000464","article-title":"Effects of the \u03b12\/\u03b13-subtype-selective GABAA receptor positive allosteric modulator KRM-II-81 on pain-depressed behavior in rats: comparison with ketorolac and diazepam","volume":"30","author":"Moerke","year":"2019","journal-title":"Behav Pharmacol"},{"key":"10.1124\/jpet.123.002070_bib32","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1042\/BST0371328","article-title":"Role of GABAA receptors in cognition","volume":"37","author":"M\u00f6hler","year":"2009","journal-title":"Biochem Soc Trans"},{"key":"10.1124\/jpet.123.002070_bib33","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1124\/jpet.108.144568","volume":"327","author":"Munro","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.123.002070_bib34","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.neuropharm.2010.10.020","article-title":"The rise of a new GABA pharmacology","volume":"60","author":"M\u00f6hler","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.123.002070_bib35","article-title":"A comparison of the \u03b12\/3\/5 selective positive allosteric modulators L-838,417 and TPA023 in preclinical models of inflammatory and neuropathic pain","volume":"2011","author":"Nickolls","year":"2011","journal-title":"Adv Pharmacol Sci"},{"key":"10.1124\/jpet.123.002070_bib36","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1124\/jpet.104.080275","article-title":"Contribution of \u03b1 1GABAA and \u03b1 5GABAA receptor subtypes to the discriminative stimulus effects of ethanol in squirrel monkeys","volume":"313","author":"Platt","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.123.002070_bib37","doi-asserted-by":"crossref","first-page":"10800","DOI":"10.1021\/acs.jmedchem.6b01332","article-title":"Synthesis and characterization of a novel \u03b3-aminobutyric acid type a (GABAA) receptor ligand that combines outstanding metabolic stability, pharmacokinetics, and anxiolytic efficacy","volume":"59","author":"Poe","year":"2016","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.123.002070_bib38","doi-asserted-by":"crossref","first-page":"6803","DOI":"10.1038\/ncomms7803","article-title":"Analgesia and unwanted benzodiazepine effects in point-mutated mice expressing only one benzodiazepine-sensitive GABAA receptor subtype","volume":"6","author":"Ralvenius","year":"2015","journal-title":"Nat Commun"},{"key":"10.1124\/jpet.123.002070_bib39","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/44579","article-title":"Benzodiazepine actions mediated by specific gamma-aminobutyric acid(A) receptor subtypes","volume":"401","author":"Rudolph","year":"1999","journal-title":"Nature"},{"key":"10.1124\/jpet.123.002070_bib40","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1017\/S1461145709000108","article-title":"The differential role of alpha1- and alpha5-containing GABA(A) receptors in mediating diazepam effects on spontaneous locomotor activity and water-maze learning and memory in rats","volume":"12","author":"Savi\u0107","year":"2009","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1124\/jpet.123.002070_bib41","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1124\/jpet.116.232421","article-title":"Antinociceptive interactions between the imidazoline I2 receptor agonist 2-BFI and opioids in rats: role of efficacy at the \u03bc-opioid receptor","volume":"357","author":"Siemian","year":"2016","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.123.002070_bib42","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/274383a0","article-title":"GABAergic modulation of benzodiazepine binding site sensitivity","volume":"274","author":"Tallman","year":"1978","journal-title":"Nature"},{"key":"10.1124\/jpet.123.002070_bib43","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nature08758","article-title":"Neural bases for addictive properties of benzodiazepines","volume":"463","author":"Tan","year":"2010","journal-title":"Nature"},{"key":"10.1124\/jpet.123.002070_bib44","article-title":"Editorial: preclinical animal models and measures of pain: improving predictive validity for analgesic drug development","volume":"3","author":"Tappe-Theodor","year":"2022","journal-title":"Front Pain Res (Lausanne)"},{"key":"10.1124\/jpet.123.002070_bib45","doi-asserted-by":"crossref","first-page":"3309","DOI":"10.1007\/s00213-015-3983-1","article-title":"Anti-hyperalgesic effects of imidazoline I2 receptor ligands in a rat model of inflammatory pain: interactions with oxycodone","volume":"232","author":"Thorn","year":"2015","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/jpet.123.002070_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.bja.2018.12.006","article-title":"Analgesic potential of PF-06372865, an \u03b12\/\u03b13\/\u03b15 subtype-selective GABAA partial agonist, in humans","volume":"123","author":"van Amerongen","year":"2019","journal-title":"Br J Anaesth"},{"key":"10.1124\/jpet.123.002070_bib47","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.pbb.2019.02.013","article-title":"The \u03b12,3-selective potentiator of GABAA receptors, KRM-II-81, reduces nociceptive-associated behaviors induced by formalin and spinal nerve ligation in rats","volume":"180","author":"Witkin","year":"2019","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1124\/jpet.123.002070_bib48","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/bs.apha.2014.11.007","article-title":"Restoring the spinal pain gate: GABA(A) receptors as targets for novel analgesics","volume":"73","author":"Zeilhofer","year":"2015","journal-title":"Adv Pharmacol"},{"key":"10.1124\/jpet.123.002070_bib49","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0304-3959(83)90201-4","article-title":"Ethical guidelines for investigations of experimental pain in conscious animals","volume":"16","author":"Zimmermann","year":"1983","journal-title":"Pain"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524178202?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524178202?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.123.002070","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T15:37:40Z","timestamp":1739979460000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524178202"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S0022356524178202"],"URL":"https:\/\/doi.org\/10.1124\/jpet.123.002070","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antinociceptive Effects of \u03b12\/\u03b13-Subtype-Selective GABAA Receptor Positive Allosteric Modulators KRM-II-81 and NS16085 in Male Rats: Behavioral Specificity","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.123.002070","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}